Indri Becomes the Fastest Growing Single Malt Brand in the World: Sells Over One Hundred Thousand Cases in Its Second Year
12.4.2024 17:09:00 EEST | Business Wire | Press release
Indri, India’s 1st and most awarded triple cask single malt, by Piccadily Distilleries, has further solidified India’s growth story with Indri-Trini becoming the ‘fastest growing single malt in the world ever’. No other single malt brand from Scotland, Japan, Taiwan or anywhere else in the world has ever been able to cross the hundred thousand (100 K) cases mark within two years of its launch. With this feat, Indri-Trini has shattered all expectations and broken into the elite club of top selling single malts in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240412989230/en/
Indri becomes the fastest growing single malt whisky in the world. (Photo: Business Wire)
With an unprecedented growth rate of 599% compared to last year, Indri is not just breaking records; it's reinventing the game. Indri has trailblazed its way to capture 30% market share in India. Piccadily Distilleries, with its ambitious expansion plans, envisions becoming one of the top 5 selling single malt brand in the world.
Since its debut in November 2021, Indri’s brand journey from inception to this extraordinary milestone has witnessed over 25 global coveted accolades including 'Best Indian Single Malt' at prestigious competitions like the World Whisky Awards and the International Whisky Competition. With notable titles such as 'Asian Whisky of the Year' and a 'Gold Medal' at the New York World Wine & Spirits Competition, Indri has made India immensely proud on a global scale. Its crowning achievement came when its Indri Diwali Collector’s Edition was declared 'Best Whisky In The World' at the Whiskies of the World Awards, surpassing Scotch and American rivals. This success has not only elevated the brand but also bolstered the reputation of Indian whiskies internationally, sparking a surge in demand for premium Indian single malts.
The rise of Indri is indicative of a seismic shift in consumer behaviour and preferences with premium sprits leading the way. As per industry reports, Indian single malts have staged a coup, outpacing their Scottish counterparts with a staggering 144% surge in 2021-22 and the momentum is only building. Early estimates by the Confederation of Indian Alcoholic Beverage Companies (CIABC) indicate that Indian single malts commanded a jaw-dropping 53% of total sales in 2023, leaving imported brands trailing behind.
“In a market once dominated by imported labels, Indri stands tall as a beacon of Indian excellence. It's not just a brand; it's a symbol of national pride, elevating the status of Indian spirits to unparalleled heights. Indri isn't just leading the charge; it's leading a revolution,” said CEO, Piccadily Distilleries, Praveen Malviya.
As Indri continues to redefine the standards of Indian single malts, Piccadily Distilleries remains dedicated to pushing boundaries, exploring new horizons, and delivering exceptional experiences to whisky enthusiasts worldwide.
Stock Ticker: (PICCADIL | 530305 | INE546C01010)
https://www.bseindia.com/stock-share-price/piccadily-agro-industries-ltd/piccadily-agro-inds/530305/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412989230/en/
Contact information
For more information, contact:
Shreya Bhattacharya – shreyab@avianwe.com | +91-9582891650
Rutvi Mehta – rutvim@avianwe.com | +91-86194 30473
Abhishek Haryson – a.haryson@piccadily.com | +91 9891356547
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom